Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the fourth quarter of this year.
The trial features a double-dummy, double-blinded design. It assesses the safety, tolerability and pharmacokinetics of three dose groups of inhaled PUR3100 with intravenous (IV) placebo.
Pulmatrix is comparing its treatment to a single dose of IV DHE (DHE mesylate injection) with inhaled placebo. The evaluation includes 26 healthy subjects with at least six subjects in each of the four groups.
Get the full story at our sister site, Drug Delivery Business News.